Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis

Pediatric Pulmonology

Volumn 48, Issue 7, 2013, Pages 666-673

  Wagener, Jeffrey S ^a   Rasouliyan, Lawrence ^b   Vandevanter, Donald R ^c   Pasta, David J ^b   Regelmann, Warren E ^d   Morgan, Wayne J ^e   Konstan, Michael W ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b ICON Late Phase and Outcomes Research   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

antibiotics; cystic fibrosis; epidemiology; pulmonary exacerbation

Indexed keywords

ANTIBIOTIC AGENT;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; DISEASE EXACERBATION; DRUG CHOICE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CYSTIC FIBROSIS; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY EXACERBATION; SCHOOL CHILD;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGE FACTORS; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84879411129     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22652     Document Type: Article

References (43)

1. Ferkol T, Rosenfeld M, Milla CE,. Cystic fibrosis pulmonary exacerbations. J Pediatr 2006; 148: 259-264.
2. Dakin C, Henry RL, Field P, Morton J,. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001; 31: 436-442.
3. Marshall BC,. Pulmonary exacerbations in cystic fibrosis: It's time to be explicit ! Am J Respir Crit Care Med 2004; 169: 781-782.
4. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B,. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001; 139: 359-365.
5. Orenstein DM, Pattishall EN, Nixon PA, Ross EA, Kaplan RM,. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis. Chest 1990; 98: 1081-1084.
6. Bradley J, McAlister O, Elborn S,. Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis. Eur Respir J 2001; 17: 712-715.
7. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW,. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002; 121: 64-72.
8. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151: 134-139.
9. VanDevanter DR, Wagener JS, Pasta DJ, Elkin E, Jacobs JR, Morgan WJ, Konstan MW,. Pulmonary outcome prediction (pop) tools for cystic fibrosis patients. Pediatr Pulmonol 2010; 45: 1156-1166.
10. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC,. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153: 345-352.
11. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML,. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166: 1550-1555.
12. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL,. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
13. Ellaffi M, Vinsonneau C, Coste J, Hubert D, Burgel PR, Dhainaut JF, Dusser D,. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med 2005; 171: 158-164.
14. Kraynack NC, Gothard MD, Falletta LM, McBride JT,. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 2011; 46: 870-881.
15. Smyth A,. Update on treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 2006; 12: 440-444.
16. Flume PA, Mogayzel PJ, Jr., Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC,. Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180: 802-808.
17. Goss CH, Burns JL,. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007; 62: 360-367.
18. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME,. Effect of aerosolized recombinant human dnase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group. N Engl J Med 1994; 331: 637-642.
19. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 328: 1740-1746.
20. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III., Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 2003; 290: 1749-1756.
21. Murphy TD, Anbar RD, Lester LA, Nasr SZ, Nickerson B, VanDevanter DR, Colin AA,. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004; 38: 314-320.
22. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT,. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-240.
23. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al. A CFTR potentiator in patients with cystic fibrosis and the g551d mutation. N Engl J Med 2011; 365: 1663-1672.
24. Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ, Jr., Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med 2010; 182: 1137-1143.
25. VanDevanter DR, O'Riordan MA, Blumer JL, Konstan MW,. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res 2010; 11: 137.
26. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH,. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182: 627-632.
27. Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH,. Return of fev1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010; 45: 127-134.
28. Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH,. Pulmonary exacerbations are associated with subsequent fev1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011; 46: 393-400.
29. Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, Konstan MW, Light MJ, Rabin HR, Regelmann WE, et al. Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999; 28: 231-241.
30. Wang X, Dockery DW, Wypij D, Gold DR, Speizer FE, Ware JH, Ferris BG, Jr., Pulmonary function growth velocity in children 6 to 18 years of age. Am Rev Respir Dis 1993; 148: 1502-1508.
31. Hankinson JL, Odencrantz JR, Fedan KB,. Spirometric reference values from a sample of the general U.S. Population. Am J Respir Crit Care Med 1999; 159: 179-187.
32. Stenbit AE, Flume PA,. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 17: 442-447.
33. Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, Johnson CA, Konstan MW, Regelmann WE,. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004; 37: 400-406.
34. Wat D, Gelder C, Hibbitts S, Cafferty F, Bowler I, Pierrepoint M, Evans R, Doull I,. The role of respiratory viruses in cystic fibrosis. J Cyst Fibros 2008; 7: 320-328.
35. Clifton IJ, Kastelik JA, Peckham DG, Hale A, Denton M, Etherington C, Conway SP,. Ten years of viral and non-bacterial serology in adults with cystic fibrosis. Epidemiol Infect 2008; 136: 128-134.
36. Smyth AR, Smyth RL, Tong CY, Hart CA, Heaf DP,. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child 1995; 73: 117-120.
37. Lipuma JJ,. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23: 299-323.
38. Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, Grenet D, Sermet-Gaudelus I, Ramel S, Cracowski C, et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother 2009; 53: 3650-3656.
39. Blumer JL, Saiman L, Konstan MW, Melnick D,. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005; 128: 2336-2346.
40. Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M,. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. J Cyst Fibros 2008; 7: 142-146.
41. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Redding G, Rubio T, et al. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999; 134: 413-421.
42. de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, Paterson N, Jackson M, Lougheed MD, Kumar V, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011; 66: 680-685.
43. Johnson C, Butler SM, Konstan MW, Morgan W, Wohl ME,. Factors influencing outcomes in cystic fibrosis: A center-based analysis. Chest 2003; 123: 20-27.